IRIS
BALLESTRERO, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 20.992
Totale 20.992
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 20.992
Totale 20.992
Salva come PNG Salva come JPEG
Città #
Genova 15.339
Rapallo 2.703
Genoa 2.455
Vado Ligure 440
Bordighera 55
Totale 20.992
Salva come PNG Salva come JPEG
Nome #
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. 197
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of AKT-mediated gene repression 176
High frequency of trisomy 8 in acute promyelocytic leukemia: a fluorescence in situ hybridization study. 175
1222 POSTER Chemical Screening for Potentiators of Lapatinib Activity in Human Breast Cancer 175
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry 173
1221 POSTER Chemical-genetic Screenings for Synthetic-lethal Interactions in Breast Cancer 172
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 169
P-334 * Radiological assessments for select patients in neoadjuvant setting in rectal cancer: monoinstitutional experience 168
Reverse-transcriptase polymerase chain reaction of the maspin gene in the detection of bone marrow breast carcinoma cell contamination. 164
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors and DNA repair. 163
Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics 158
Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. 157
Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies. 157
Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors. 153
APO866 activity in hematologic malignancies: a preclinical in vitro study. 150
Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial 149
Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. 147
5-fluorouracil causes endothelial cell senescence: Potential protective role of glucagon-like peptide 1 146
Discovery of novel and selective SIRT6 inhibitors. 145
Ras-induced resistance to lapatinib is overcome by MEK inhibition 144
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. 144
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia 143
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation 143
A multi-scale approach to colorectal cancer: from a biochemical- interaction signaling-network level, to multi-cellular dynamics of malignant transformation. Interplay with mutations and onco-protein inhibitor drugs. 142
Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes. possible relevance to the assays for the detection of micrometastatic breast cancer 141
Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. 141
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 140
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients 140
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 139
Uncovering the genomic heterogeneity of multifocal breast cancer 139
Lymph node number, surface area and lymph node ratio are important prognostic indicators in neoadjuvant chemoradiotherapy treated rectal cancer 138
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società  Italiana di Medicina Interna) Study 137
Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. 137
Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. 136
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. 136
DNA aneuploidy relationship with patient age and tobacco smoke in OPMDs/OSCCs 135
Sirt6 regulates dendritic cell differentiation, maturation, and function 134
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 133
Abstract 49: Agreement of immunohistochemistry, fluorescence in situ hybridization, real-time quantitative polymerase-chain reaction, and quantitative reverse transcriptase PCR for Her-2/Neu status assessment in breast cancer patients: a single center, retrospective m 132
Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. 132
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma 130
Parameter Space Exploration within Dynamic Simulations of Signaling Networks 129
Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations 129
Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF 128
Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer 128
Squalene epoxidase as a promising metabolic target in cancer treatment 128
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 128
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more. 128
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition 127
HMGA2 overexpression in plycythemia vera with t(12;21) (q14;q22) 127
Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin. 126
A new human calpastatin skipped of the inhibitory region protects calpain-1 from inactivation and degradation 126
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 125
Platelets as scavengers of neutrophil-derived oxidants: a possible defence mechanism at sites of vascular injury. 122
Germline mutations in the von Hippel-Lindau gene in Italian patients. 121
Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide and cisplatin (CEP) 119
Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. 119
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 119
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma 118
High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule 118
Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. 117
Tumor cell lysis by activated human neutrophils: analysis of neutrophil-delivered oxidative attack and role of leukocyte function-associated antigen 1. 117
Chemical-genetic Screenings for Synthetic-lethal Interactions in Breast Cancer 117
Fasting potentiates the anticancer activity of tyrosin kinase inhibitors by strenghtening MAPK signalling inhibition. 117
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial 117
Nicotinamide Phosphoribosyltransferase As A Target In Inflammation-Related Disorders. 116
Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments. Concordance with experimental results. 116
Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer. 116
Protective effects of carvedilol against doxorubicin-induced apoptosis in cardiac muscle cells 116
The use of dendritic cells in cancer immunotherapy. 115
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 115
Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer 114
Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer 114
The proteasome and its inhibitors in immune regulation and immune disorders. 113
Dynamic Simulations of Pathway Cross-talks Relevant in Colorectal Cancer: A Quantitative Parameter Sensitivity Analysis 113
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. 113
Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions. 113
The effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer. 112
The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level 112
Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer 111
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 111
Immunotherapy with dendritic cells for cancer 111
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. 110
Monocyte-derived macrophages as helper cells in monocyte-mediated cytolysis. 110
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 110
Autologous peripheral blood stem cells (PBSC) in breast cancer. 109
Reliability and reproducibility of a RNA preamplification method for low-density array analysis from formalin-fixed paraffin-embedded breast cancer samples. 108
Activation of the death receptor apoptosis pathway by TRAIL overcomes anticancer drug resisitance in antiapoptotic bcl-2 family members expressing lymphoma cells 108
Augmentation of neutrophil-mediated erythrocyte lysis by cells derived in vitro from human monocytes. 108
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases 108
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis 107
Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. 107
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. 106
Polypharmacy in older people: Lessons from 10 years of experience with the REPOSI register 106
Rejuvenating sirtuins: the rise of a new family of cancer drug targets 106
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. 105
DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. 105
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. 105
Circulating tumor DNA using tagged targeted deep sequencing to assess minimal residual disease in breast cancer patients undergoing neoadjuvant chemotherapy 104
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents 103
Totale 12.936
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.458
article - articoli 63.482
book - libri 0
conference - conferenze 1.323
curatela - curatele 0
other - altro 0
patent - brevetti 76
selected - selezionate 0
volume - volumi 577
Totale 130.916
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.261 0 0 229 363 516 621 925 443 517 873 584 190
2020/20211.823 120 165 105 164 159 121 88 176 159 227 192 147
2021/20222.733 94 187 154 367 143 213 181 543 154 241 140 316
2022/20233.257 290 299 23 363 558 487 32 246 483 22 398 56
2023/20241.867 80 215 40 250 151 320 102 157 90 49 111 302
2024/2025579 209 322 48 0 0 0 0 0 0 0 0 0
Totale 21.454